文献速递肝病

预测肝硬化患者发生肝性脑病的风险评分:基于人群的队列研究

A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis.
PubMed 文献 · Hepatology · 2018-05-14

研究基于美国密歇根、印第安纳和俄亥俄州退伍军人管理局2005年1月1日至2010年12月31日期间1979例基线无肝性脑病的肝硬化患者,构建并验证预测肝性脑病发生的风险评分。5年内43.7%患者发生肝性脑病;多变量模型显示胆红素升高(HR 1.07,95%CI 1.05-1.09)和非选择性β受体阻滞剂使用(HR 1.34,95%CI 1.09-1.64)为危险因素,白蛋白升高(HR 0.54,95%CI 0.48-0.59)和他汀类使用(HR 0.80,95%CI 0.65-0.98)为保护因素。基线模型和纵向模型AUC分别为0.68(95%CI 0.66-0.70)和0.73(95%CI 0.71-0.75)。

要点

  • 肝硬化患者5年内肝性脑病发生率为43.7%。
  • 胆红素升高和非选择性β受体阻滞剂使用与肝性脑病风险升高相关。
  • 白蛋白升高和他汀类使用与肝性脑病风险降低相关。

核心结论

  • 肝硬化患者可通过一个简单的风险评分进行肝性脑病风险分层,该评分考虑了临床数据的变化。
  • 研究数据还提示他汀类在减少包括肝性脑病在内的肝硬化并发症方面可能发挥作用。

研究设计与样本

  • 基于人群的队列研究,纳入美国密歇根、印第安纳和俄亥俄州退伍军人管理局2005年1月1日至2010年12月31日期间基线无肝性脑病的全部肝硬化患者1979例。
  • 使用人口学、临床、实验室和药房数据,主要结局为肝性脑病的发生。
  • 风险评分基于基线和纵向数据(每年更新参数)构建,并使用自举法验证。

主要发现

  • 队列平均年龄58.0±8.3岁,36%有丙型肝炎,17%有腹水。
  • 基线时阿片类、苯二氮䓬类、他汀类和非选择性β受体阻滞剂使用率分别为24%、13%、17%和12%。
  • 5年内863例(43.7%)发生肝性脑病。
  • 多变量模型中,肝性脑病危险因素包括胆红素升高(HR 1.07,95%CI 1.05-1.09)和非选择性β受体阻滞剂使用(HR 1.34,95%CI 1.09-1.64),保护因素包括白蛋白升高(HR 0.54,95%CI 0.48-0.59)和他汀类使用(HR 0.80,95%CI 0.65-0.98)。
  • 阿片类和苯二氮䓬类使用等其他临床因素无预测作用。

关键数值与推荐

  • 基线模型和纵向模型使用四个显著变量的AUC分别为0.68(95%CI 0.66-0.70)和0.73(95%CI 0.71-0.75)。
  • 纵向模型中评分≤0分对应1年肝性脑病概率6%,评分>20分对应1年风险38%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Over 40% of patients with cirrhosis will develop hepatic encephalopathy (HE). HE is associated with decreased survival, falls, motor vehicle accidents, and frequent hospitalization. Accordingly, we aimed to develop a tool to risk-stratify patients for HE development. We studied a population-based cohort of all patients with cirrhosis without baseline HE (n = 1,979) from the Veterans Administration from Michigan, Indiana, and Ohio (January 1, 2005-December 31, 2010) using demographic, clinical, laboratory, and pharmacy data. The primary outcome was the development of HE. Risk scores were constructed with both baseline and longitudinal data (annually updated parameters) and validated using bootstrapping. The cohort had a mean age of 58.0 ± 8.3 years, 36% had hepatitis C, and 17% had ascites. Opiates, benzodiazepines, statins, and nonselective beta-blockers were taken at baseline by 24%, 13%, 17%, and 12%, respectively. Overall, 863 (43.7%) developed HE within 5 years. In multivariable models, risk factors (hazard ratio, 95% confidence interval) for HE included higher bilirubin (1.07, 1.05-1.09) and nonselective beta-blocker use (1.34, 1.09-1.64), while higher albumin (0.54, 0.48-0.59) and statin use (0.80, 0.65-0.98) were protective. Other clinical factors, including opiate and benzodiazepine use, were not predictive. The areas under the receiver operating characteristics curve for HE using the four significant variables in baseline and longitudinal models were 0.68 (0.66-0.70) and 0.73 (0.71-0.75), respectively. Model effects were validated and converted into a risk score. A score ≤0 in our longitudinal model assigns a 6% 1-year probability of HE, while a score >20 assigns a 38% 1-year risk. CONCLUSION: Patients with cirrhosis can be stratified by a simple risk score for HE that accounts for changing clinical data; our data also highlight a role for statins in reducing cirrhosis complications including HE. (Hepatology 2017).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Tapper EB, Parikh ND, Sengupta N, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology. 2018. PMID: 29091289. doi:10.1002/hep.29628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。